After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved.



1245722172

Reuters

United Kingdom

US FDA says Lilly's weight-loss drug no longer in shortage

Eli Lilly's blockbuster weight-loss drug is no longer in shortage in the United States, the U.S. Food and Drug Administration's website showed on Wednesday.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Woodbridge Company

Eli Lilly’s weight-loss drug no longer in shortage, FDA says

The Washington Post

Jeff Bezos

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and obesity medications Mounjaro and Zepbound, was declared in shortage in December 2022. The shortage has been attributed to increased demand as interest in GLP-1 medications has soared.…

Mounjaro and Zepbound no longer in shortage

The Hill

Nexstar Media Group

Washington

District of Columbia

United States

Eli Lilly &amp; Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.

Bloomberg

Michael Bloomberg

The Vanguard Group

Howard Buffett

BlackRock

Lilly Weight-Loss Drug Copycats Dealt Blow as Shortage Ends

(Reuters) -Eli Lilly’s weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration’s website showed on Wednesday. Mounjaro has been on the FDA’s shortage list since late 2022, while Zepbound was added to the list in April this year. The drugmaker had begun selling vials of the lowest starter dose of Zepbound in the United States through its direct-to-consumer website to help increase its …

WTVB

Midwest Communications

US FDA says Lilly’s weight-loss drug no longer in shortage

(Reuters) -Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday. Mounjaro has been on the FDA's shortage list since late 2022, while Zepbound was...

The Mighty 790 KFGO

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and obesity medications Mounjaro and Zepbound, was declared in shortage in December 2022. The shortage has been attributed to increased demand as interest in GLP-1 medications has soared.… Source link

Mounjaro and Zepbound no longer in shortage

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics